Clinical Trials
4 trialsNCT04407442 2024-04-30
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
University of California, San Francisco
Phase 2 Terminated
NCT01155583 2020-11-16
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01050790 2018-06-26
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
Virginia Commonwealth University
Phase NA Completed
NCT00545519 2013-04-23
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
Washington University School of Medicine
Phase 1 Completed